Abstract
Background Previous studies have demonstrated that perioperative blood transfusion (BT) is associated with a significantly increased risk of cancer recurrence and mortality after radical cystectomy (RC). Recently, it was shown for the first time that intraoperative transfusion has a detrimental effect on cancer survival. The aim of the current study was to validate this finding in a single European institution. Patients and Methods The study focused on 1490 consecutive nonmetastatic bladder cancer patients treated with RC at a single tertiary care referral center between January 1990 and August 2013. Kaplan-Meier analyses and Cox regression analyses were used to assess the effect of timing of BT administration (no transfusion vs. intraoperative transfusion vs. postoperative transfusion vs. intraoperative and postoperative transfusion) on cancer-specific mortality (CSM), overall mortality (OM), and disease recurrence. Results Mean age at the time of RC was 67 years. Overall, 322 (21.6%) patients received intraoperative BT and 97 (6.5%) received postoperative BT. At a mean follow-up time of 125 months (median, 110 months), the 5- and 10-year CSM rate was 846 (58%) and 715 (48%), respectively. In multivariable analyses patients who received intraoperative BT had greater risk of disease recurrence (hazard ratio [HR], 1.24; P .2). Conclusion Our study confirms that intraoperative, but not postoperative BT, are related to a detrimental effect on survival after RC. These results should be take into account by physicians to administer BT using the correct timing.
| Original language | English |
|---|---|
| Pages (from-to) | 562-567 |
| Number of pages | 6 |
| Journal | Clinical Genitourinary Cancer |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1 2015 |
Fingerprint
Keywords
- Bladder cancer
- Cancer specific mortality
- Intraoperative transfusion
- Radical cystectomy
ASJC Scopus subject areas
- Oncology
- Urology
Cite this
Effect of allogeneic intraoperative blood transfusion on survival in patients treated with radical cystectomy for nonmetastatic bladder cancer : Results from a single high-volume institution. / Moschini, Marco; Dell'Oglio, Paolo; Capogrosso, Paolo; Cucchiara, Vito; Luzzago, Stefano; Gandaglia, Giorgio; Zattoni, Fabio; Briganti, Alberto; Damiano, Rocco; Montorsi, Francesco; Salonia, Andrea; Colombo, Renzo.
In: Clinical Genitourinary Cancer, Vol. 13, No. 6, 01.12.2015, p. 562-567.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of allogeneic intraoperative blood transfusion on survival in patients treated with radical cystectomy for nonmetastatic bladder cancer
T2 - Results from a single high-volume institution
AU - Moschini, Marco
AU - Dell'Oglio, Paolo
AU - Capogrosso, Paolo
AU - Cucchiara, Vito
AU - Luzzago, Stefano
AU - Gandaglia, Giorgio
AU - Zattoni, Fabio
AU - Briganti, Alberto
AU - Damiano, Rocco
AU - Montorsi, Francesco
AU - Salonia, Andrea
AU - Colombo, Renzo
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background Previous studies have demonstrated that perioperative blood transfusion (BT) is associated with a significantly increased risk of cancer recurrence and mortality after radical cystectomy (RC). Recently, it was shown for the first time that intraoperative transfusion has a detrimental effect on cancer survival. The aim of the current study was to validate this finding in a single European institution. Patients and Methods The study focused on 1490 consecutive nonmetastatic bladder cancer patients treated with RC at a single tertiary care referral center between January 1990 and August 2013. Kaplan-Meier analyses and Cox regression analyses were used to assess the effect of timing of BT administration (no transfusion vs. intraoperative transfusion vs. postoperative transfusion vs. intraoperative and postoperative transfusion) on cancer-specific mortality (CSM), overall mortality (OM), and disease recurrence. Results Mean age at the time of RC was 67 years. Overall, 322 (21.6%) patients received intraoperative BT and 97 (6.5%) received postoperative BT. At a mean follow-up time of 125 months (median, 110 months), the 5- and 10-year CSM rate was 846 (58%) and 715 (48%), respectively. In multivariable analyses patients who received intraoperative BT had greater risk of disease recurrence (hazard ratio [HR], 1.24; P .2). Conclusion Our study confirms that intraoperative, but not postoperative BT, are related to a detrimental effect on survival after RC. These results should be take into account by physicians to administer BT using the correct timing.
AB - Background Previous studies have demonstrated that perioperative blood transfusion (BT) is associated with a significantly increased risk of cancer recurrence and mortality after radical cystectomy (RC). Recently, it was shown for the first time that intraoperative transfusion has a detrimental effect on cancer survival. The aim of the current study was to validate this finding in a single European institution. Patients and Methods The study focused on 1490 consecutive nonmetastatic bladder cancer patients treated with RC at a single tertiary care referral center between January 1990 and August 2013. Kaplan-Meier analyses and Cox regression analyses were used to assess the effect of timing of BT administration (no transfusion vs. intraoperative transfusion vs. postoperative transfusion vs. intraoperative and postoperative transfusion) on cancer-specific mortality (CSM), overall mortality (OM), and disease recurrence. Results Mean age at the time of RC was 67 years. Overall, 322 (21.6%) patients received intraoperative BT and 97 (6.5%) received postoperative BT. At a mean follow-up time of 125 months (median, 110 months), the 5- and 10-year CSM rate was 846 (58%) and 715 (48%), respectively. In multivariable analyses patients who received intraoperative BT had greater risk of disease recurrence (hazard ratio [HR], 1.24; P .2). Conclusion Our study confirms that intraoperative, but not postoperative BT, are related to a detrimental effect on survival after RC. These results should be take into account by physicians to administer BT using the correct timing.
KW - Bladder cancer
KW - Cancer specific mortality
KW - Intraoperative transfusion
KW - Radical cystectomy
UR - http://www.scopus.com/inward/record.url?scp=84947865872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947865872&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2015.04.009
DO - 10.1016/j.clgc.2015.04.009
M3 - Article
C2 - 26004301
AN - SCOPUS:84947865872
VL - 13
SP - 562
EP - 567
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 6
ER -